Loke J, Upasani V, Gaskell C, Fox S, Fletcher R, Thomas C, Hopkins L, Kumari A, Tang T, Yafai E, Boucher R, Homer V, Toth A, Chan YLT, Randall K, Rider T, O’Nions J, Drew V, Pillai A, Dungarwalla M, Murray D, Khan A, Wandroo F, Moore S, Kirshnamurthy P, Huang YWJ, Knapper S, Byrne J, Zhao R, Craddock C, Parry H, Moss P, Stanworth SJ, Lowe DM. (2023), Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes. British Journal of Haematology, 202:498-503.
Loke J, Metzner M, Boucher R, Jackson A, Hopkins L, Pavlu J, Tholouli E, Drummond M, Peniket A, Bishop R, Fox S, Vyas P, Craddock C. (2022), Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy. British Journal of Haematology, 196(2):368-73.
Fox CP, Ali AS, McIlroy G, Thust S, Martinez-Calle N, Jackson AE, Hopkins LM, Thomas CM, Kassam S, Wright J, Chaganti S, Smith J, Chau I, Culligan D, Linton KM, Collins GP, Ferreri AJM, Lewis D, Davies AJ, Johnson R, Auer DP, Cwynarski K. (2021), A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Advances, 5(20):4073.
Eyre TA, Hildyard C, Hamblin A, Ali AS, Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A, Rule S, Cwynarski K, Barrington SF, Warbey V, Wrench D, Barrans S, Hirst CS, Panchal A, Roudier MP, Harrington EA, Davies A, Collins GP. (2019), A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. Hematological Oncology, 37(4):352-59.
Craddock C, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai SP, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P. (2017), Outcome of Azacitidine Therapy in Acute Myeloid Leukemia is not Improved by Concurrent Vorinostat Therapy but is Predicted by a Diagnostic Molecular Signature. Clinical Cancer Research, 23:6430-40.
Dudley L, Gamble C, Preston J, Buck D, The EPIC Patient Advisory Group, Hanley B, Williamson P, Young B. (2015), What difference does patient and public involvement make and what are its pathways to impact? Qualitative study of patients and researchers from a cohort of randomised clinical trials. PLOS ONE, 10(6):e0128817
Dudley L, Gamble C, Allam A, Bell P, Buck D, Goodare H, Hanley B, Preston J, Walker A, Williamson P, Young B. (2015), A little more conversation please? Qualitative study of researchers’ and patients’ interview accounts of training for patient and public involvement in clinical trials. Trials, 16:190. DOI 10.1186/s13063-015-0667-4
Buck D, Gamble C, Dudley L, Preston J, Hanley B, Williamson PR, Young B. (2014), The EPIC Patient Advisory Group. From plans to actions in patient and public involvement: qualitative study of documented plans and the accounts of researchers and patients sampled from a cohort of clinical trials. BMJ Open, 4:e006400 doi:10.1136/bmjopen-2014-006400
Gamble C, Dudley L, Allam A, Bell P, Buck D, Goodare H, Hanley B, Preston J, Walker A, Williamson P, Young B. (2014), Patient and public involvement in the early stages of clinical trial development: a systematic cohort investigation. BMJ Open, 4:e005234. doi:10.1136/bmjopen-2014-005234